Oral administration of pyrophosphate inhibits connective tissue calcification by Dedinszki, Dóra et al.
Report
Oral administration of pyrophosphate inhibits
connective tissue calcification
Dóra Dedinszki1,†, Flóra Szeri1,†, Eszter Kozák1,2, Viola Pomozi1,3, Natália T}okési1, Tamás Róbert
Mezei4,5, Kinga Merczel1, Emmanuel Letavernier6,7,8, Ellie Tang6,7, Olivier Le Saux3, Tamás Arányi1,9,
Koen van de Wetering10,‡ & András Váradi1,*
Abstract
Various disorders including pseudoxanthoma elasticum (PXE) and
generalized arterial calcification of infancy (GACI), which are
caused by inactivating mutations in ABCC6 and ENPP1, respec-
tively, present with extensive tissue calcification due to reduced
plasma pyrophosphate (PPi). However, it has always been assumed
that the bioavailability of orally administered PPi is negligible.
Here, we demonstrate increased PPi concentration in the circula-
tion of humans after oral PPi administration. Furthermore, in
mouse models of PXE and GACI, oral PPi provided via drinking
water attenuated their ectopic calcification phenotype. Noticeably,
provision of drinking water with 0.3 mM PPi to mice heterozygous
for inactivating mutations in Enpp1 during pregnancy robustly
inhibited ectopic calcification in their Enpp1/ offspring. Our work
shows that orally administered PPi is readily absorbed in humans
and mice and inhibits connective tissue calcification in mouse
models of PXE and GACI. PPi, which is recognized as safe by the
FDA, therefore not only has great potential as an effective and
extremely low-cost treatment for these currently intractable
genetic disorders, but also in other conditions involving connective
tissue calcification.
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Introduction
Physiological mineralization is essential for the normal development
of vertebrates and restricted to specific sites of the body. In
mammals, biominerals predominantly consist of calcium and phos-
phate, which form hydroxyapatite. Vertebrates have evolved mecha-
nisms permitting crystallization of calcium and phosphate only at
specific sites.
Pyrophosphate (PPi) is a central factor in the prevention of the
precipitation of calcium and phosphate in soft peripheral tissues (for
a recent review see: Orriss et al, 2016). The liver is the most impor-
tant source of circulatory PPi, via a pathway depending on ABCC6-
mediated ATP release (Jansen et al, 2013, 2014), though the exact
molecular mechanism of ATP release and the actual substrate of
ABCC6 is not known. Within the liver vasculature, released ATP is
rapidly converted into AMP and PPi by the ectoenzyme ectonu-
cleotide pyrophosphatase phosphodiesterase 1 (ENPP1; Jansen et al,
2014). Inactivating mutations in the genes encoding enzymes
involved in PPi homeostasis result in rare hereditary calcification
disorders which include pseudoxanthoma elasticum (PXE, OMIM
264800), generalized arterial calcification of infancy (GACI, OMIM
208000), arterial calcification due to CD73 deficiency (ACDC,
OMIM 211800), and Hutchinson–Gilford Progeria Syndrome (HGPS,
OMIM 176670). Absence of functional ABCC6 results in PXE, a late
onset ectopic calcification disorder, with lesions found in the skin,
eyes, and cardiovascular system (Bergen et al, 2000; Le Saux et al,
2000; Ringpfeil et al, 2000). Biallelic mutations in ENPP1 cause
GACI, a condition that can become life threatening shortly after
birth due to massive calcification of the large- and medium-sized
arteries (Rutsch et al, 2003). While in PXE plasma PPi concentration
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is reduced to 40% of normal (Jansen et al, 2014), GACI patients
have virtually no PPi in their blood, which explains the severity of
the disease (Rutsch et al, 2003). Other gene products are also
involved in soft tissue calcification affecting PPi homeostasis, such
as ANK, which mediates the intracellular to extracellular channeling
of PPi (Ho et al, 2000), though it does not play a role in maintaining
plasma PPi.
Because reduced PPi concentrations in the circulation underlie
the ectopic calcification disorders PXE and GACI, a logical treatment
for these disorders would be PPi supplementation. Due to the neces-
sity to treat patients lifelong, oral administration would be preferred
for such a treatment. Phosphatases are abundantly present in the
gut (Ferguson et al, 1968); therefore, it has been always claimed
that orally administered PPi cannot reach the circulation and there-
fore is not effective in inhibiting ectopic calcification (Orriss et al,
2016). We have tested this assumption in healthy human individu-
als and in mouse models reflecting two human hereditary calcifi-
cation disorders, PXE and GACI.
Results
Uptake of PPi in humans and mice
First, we tested whether orally consumed PPi is absorbed in
humans. Healthy human volunteers (fasting) ingested a solution of
tetrasodium pyrophosphate (Na4PPi), resulting in a dose of 40, 67,
or 98 mg/kg of body weight (43, 72, 110 mM, pH 8.0, respectively).
The ingested amounts of Na4PPi correspond to 13–33% of the maxi-
mal tolerable daily intake published by the World Health Organiza-
tion, WHO (http://www.inchem.org/documents/jecfa/jeceval/jec_
2259.htm). This resulted in substantially elevated plasma PPi levels
(Fig 1A; with individual differences as shown on Fig 1B) when 98
and 67 mg/kg Na4PPi was taken, while the plasma PPi level was
increased only moderately in individuals taking 40 mg/kg (Fig 1A).
The time needed to get the plasma PPi back to the baseline level
was 240 min at dose 67 mg/kg and 360 min at dose 98 mg/kg
(Fig 1A). These data indicate a dose- and time-dependent elevation
of plasma PPi concentration. From the data presented in Fig 1A, we
calculated the following pharmacokinetic parameters: tmax = 36.7 
13.2 min, Cmax = 3.9  1.6 lM, t1/2 = 44.7  16.7 min (single
exponential decay) when 98 mg Na4PPi per kg body weight was
given.
Next, we investigated whether supplementation via the drink-
ing water increased plasma PPi levels in mice. In preliminary
experiments, we found that in half of the animals, plasma PPi did
not increase. This is most probably due to “non-synchronized”
drinking by the animals. We therefore directly delivered PPi into
the oral cavity, stomach, or small intestine (Fig 1C) and placed
ligatures downstream and/or upstream of the site of administra-
tion to prevent any transfer of PPi. Unexpectedly, PPi was remark-
ably well absorbed from all sites tested and we followed the
uptake of PPi (50 mM, 200 ll) delivered directly to the stomach
over time. PPi was rapidly absorbed from the stomach (Fig 1D)
and, as expected, its plasma concentrations depended on the dose
given (Fig 1E).
Oral PPi inhibits ectopic calcification in Abcc6/ mice
Abcc6/ mice recapitulate human PXE, with calcifying lesions
found in skin, eyes, and blood vessels (Gorgels et al, 2005; Klement
et al, 2005). A drawback of the Abcc6/ mouse model is the rela-
tively late onset of the first symptoms, making it less convenient for
rapid screening of new treatments. However, cryo-injury applied to
the heart results in calcified lesions within 3–6 days (Doehring et al,
2006), a phenomenon fully dependent on the absence of Abcc6
(Brampton et al, 2014). The lesions showed hydroxyapatite crystal
nature as determined by transmission electron microscopy (Aher-
rahrou, 2003). Next, we determined whether orally administered
PPi was able attenuating induced cardiac calcification in PXE mice.
PPi provided via the drinking water potently inhibited calcification
(PPi was provided in the drinking water a day before the cryo-injury
and continued for 4 days) as shown by the reduced calcified area
(Fig 2A, calcium deposits stained by Alizarin Red). The extent of
inhibition was dose-dependent, with maximal inhibition seen at a
PPi concentration of 10 mM, though the cardiac lesions in Abcc6/
mice receiving drinking water with 1mM PPi already contained
more than twofold less calcium (Fig 2B).
A hallmark phenotype seen in Abcc6/ mice is the spontaneous
gradual calcification of the connective tissue surrounding the vibris-
sae (Klement et al, 2005). We found that providing Abcc6/ mice
PPi-containing drinking water (10 mM) after weaning received for
19 weeks greatly reduced the extent of calcification found in the
tissue surrounding the vibrissae. These data show that orally admin-
istered PPi not only inhibits the calcification seen after the applica-
tion of cryo-injury, but also potently inhibits the spontaneous
calcification seen in Abcc6/ mice (Fig 2C–E).
Oral PPi attenuates calcification in Enpp1/ (ttw) mice
Tiptoe walking (ttw) mice have an inactivating mutation in Enpp1
(Okawa et al, 1998). Due to the complete absence of Enpp1, these
◀ Figure 1. Uptake of PPi from drinking water.A Oral uptake of tetrasodium pyrophosphate in humans. Volunteers ingested tetrasodium pyrophosphate solutions of 43, 72, 110 mM, pH 8.0, resulting in a dose of
40 mg/kg (n = 10) or 67 mg/kg (n = 10) or 98 mg/kg (n = 9), respectively. Plasma PPi levels were determined before (0 min), and 30, 60, 120, 240, and 480 min after
ingestion. The insert shows the differences between the basal plasma PPi level (0 min) and that 30, 60, and 120 min after ingestion.
B Oral uptake of 98 mg/kg tetrasodium pyrophosphate (n = 9) in human indicating individual differences.
C Uptake from the oral cavity (n = 5), from the stomach (n = 5), and from the intestine (n = 5) of C57/BI6 mice after ligating the esophagus and applied oral delivery of
100 ll 50 mM PPi; or the pylorus followed by stomach delivery of 200 ll 50 mM PPi and then ligation of the esophagus; or injecting 200 ll 50 mM PPi into the
intestine after ligation of the pylorus. In each experiment, including control (n = 7), blood was collected after 15 min and PPi concentrations were determined.
D Time-course of PPi uptake from the stomach of C57/BI6 mice upon gavage delivery of 200 ll of 50 mM PPi, n = 5–11.
E Dose-dependent PPi uptake from the stomach of C57/BI6 mice upon gavage delivery of 200 ll of PPi of concentration 0 (n = 6), 1 (n = 6), 10 (n = 7), 25 (n = 7),
50 (n = 8), and 100 (n = 6) mM. Blood was collected for PPi assay after 15 min of delivery.
Data information: Data were analyzed by two-tailed Mann–Whitney nonparametric test. Results are expressed as mean  SEM.
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mice have extremely low plasma PPi levels and like GACI patients,
which develop extensive calcifications in blood vessels and joints
shortly after birth (Nitschke & Rutsch, 2012). Just like Abcc6/
mice, the Enpp1/ mice develop extensive calcification of the
dermal sheet surrounding the vibrissae. In these animals, this
phenotype shows up much earlier than in the PXE mice, however.
Orally administered PPi during pregnancy and breastfeeding
followed by oral PPi treatment of the pups, resulted in reduced
calcification of the dermal sheet surrounding the vibrissae in the
Enpp1/ mice (see Fig 3A–C). We found that treatment of
heterozygous Enpp1+/ mothers during their pregnancy with PPi
was critical to inhibit the ectopic calcification seen in their
Enpp1/ offspring: Treating Enpp1/ pups only after weaning
did not attenuate ectopic calcification (Fig 3A). We detected a
robust effect in the extent of calcification inhibition in the hind
limb arteries and in the renal arteries. When PPi in as low as
0.3 mM concentration was provided during pregnancy, calcification
was reduced to 12% of the levels found in the control group (hind
limb arteries) and to 25% (renal arteries), that is, resulted in





Figure 2. Oral PPi attenuates induced cardiac and spontaneous calcification of vibrissae in Abcc6/ mice.
A Calcification of the heart of Abcc6/ mice after 4 days of cryo-injury (drinking water, upper image) or (drinking water with 10 mM PPi, lower image).
Ca-precipitations are indicated by arrows, and calcium deposits were visualized by Alizarin Red staining. Scale bar = 1 mm.
B PPi was provided in 0 (n = 8), 1 (n = 8) or in 10 (n = 8) mM concentrations via the drinking water to Abcc6/ mice starting a day before cryo-injury for a total of
4 days. The calcium content of heart tissue was determined by complexometry.
C, D Show typical Alizarin Red-stained sections of an animal of the control group and that of the 10 mM PPi group, respectively. Abcc6/ mice were kept on 10 mM
PPi (in drinking water) starting at an age of 3 weeks (after weaning) until they were 22 weeks old. The control group was drinking tap water. Tissue blocks with the
vibrissae were removed, paraffin-embedded, sectioned, and stained with Alizarin Red for calcium deposits, scale bar = 1 mm.
E The extent of calcification, control (n = 9) and 10 mM PPi (n = 9), was quantified by morphometry as described in the Materials and Methods.
Data information: Data were analyzed by two-tailed Mann–Whitney nonparametric test. Results are expressed as mean  SEM.
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Discussion
Contrary to the general assumption, we found that PPi has bioavail-
ability in humans and mice when administered orally (Fig 1). The
observed transient elevation found in healthy volunteers (Fig 1A)
indicates that in both GACI and in PXE patients, PPi levels may be
transiently raised to the physiological level when 67 or 98 mg
Na4PPi/kg of body weight is taken. Importantly, it has been shown
that inhibition of calcification in uremic rats and in PXE mice can be
achieved by daily intraperitoneal injections of PPi triggering tran-
sient increase in plasma PPi levels (O’Neill et al, 2011; Pomozi et al,
2017). We determined a t1/2 = 44.7 min what is rather similar to
that published in rat (34.1 min; O’Neill et al, 2011).
We also demonstrated significant attenuation of calcification in
two different well-characterized mouse models of ectopic calcifi-
cation disorders, PXE and GACI when the animals were treated with
pyrophosphate orally. Furthermore, we demonstrated PPi uptake
from the oral cavity and stomach of mice allowing a portion of PPi
to escape the rapid hydrolytic decomposition presumably occurring
in the intestinal tract.
The unexpected observation that 0.3 mM PPi administration was
highly effective if applied exclusively during pregnancy (see Fig 3)
is likely due to microcrystal formation in the control-treated group
before birth. These microcrystals might be mostly absent in
Enpp1/ pups from heterozygous mothers receiving PPi during
pregnancy and would therefore not be available to accelerate the
calcification process after birth. GACI is often already diagnosed
prenatally in the third trimester or at birth (Kalal et al, 2012) when
the calcification is already present. The results in the Enpp1/ mice
suggest that under these conditions oral PPi may not be effective in
stopping the progression of calcification unless it is started earlier.
In summary, oral administration may represent a simple route to
achieve therapeutic levels of the physiological, non-toxic metabolite
PPi in the blood circulation. Our data indicate that oral PPi has
potential to treat two currently incurable diseases, PXE and GACI.
Importantly, oral PPi might have broader applicability and be useful
in other conditions involving ectopic calcification, such as hyperc-
holesterolemia (Hoeg et al, 1994), diabetes (Kreines et al, 1985),
chronic renal insufficiency (Moe & Chen, 2004), b-thalassemia (Aes-
sopos et al, 1992), and heterotopic ossification of traumatized
muscle (Jackson et al, 2009). The risk of orally administrated PPi to
patients is probably negligible as the WHO considers PPi a non-
toxic, physiological, metabolite with a high maximal tolerable daily
intake value (MTDI) (http://www.inchem.org/documents/jecfa/je
ceval/jec_2259.htm). Moreover, it is extensively used as a food
additive, and the Code for Federal Regulation by the FDA states:
“This substance is generally recognized as safe when used in accor-
dance with good manufacturing practice” (http://www.accessdata.
fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=582.6787). It is
also worth noting that PPi would represent a low-cost treatment of
connective tissue calcification disorders.
Materials and Methods
Human study approval
The human uptake studies were approved by the National Review
Board of the Ministry of Health, Hungary (ETT TUKEB). The actual
permit based on the above approval has been issued by National
Public Health and Medical Officer Service (A´NTSZ, authorization
number: IF-15816-4/2016). Informed consent was obtained from
each volunteer prior to the study and experiments conformed to the
principles of Declaration of Helsinki what is indicated in the above
document. All patient samples were handled in anonymized form
also approved by the above document.
Animals and animal studies
The RCNS, Hungarian Academy of Sciences Institutional Animal
Care and Use Committees, approved the animal studies and were
conducted according to national guidelines.
C57BL/6J mice designated as wild type were derived from
mice purchased from The Jackson Laboratories. Abcc6/ mice
were generated on 129/Ola background and backcrossed into a
C57BL/6J > 10 times. Ttw (Enpp1/) mice (Okawa et al, 1998)
were bred heterozygous due to the severe phenotype seen in the
null animals. Both male and female, age-matched Abcc6/,
Enpp1/, and wild-type mice were used. For uptake studies,
15-week-old C57/BI6 animals were used. In cryo-injury calcifi-
cation experiments, 12-week-old Abcc6/ animals were studied.
Calcification of the vibrissae of Abcc6/ mice was determined in
◀ Figure 3. Prenatal PPi treatment of the Enpp1/ mice attenuates calcification of the tissue surrounding the vibrissae and the arteries of the hind limbsand kidneys.
A Calcium content of the tissue blocks of the vibrissae. The heterozygous mothers and their offspring were kept on tap water until the pups were 30 days old
(“control”, n = 11); Group 1: as the control group, but for 9 days on 10 mM PPi solution after weaning at day 21 (n = 8); Group 2: the mothers and the pups were
kept on 10 mM PPi during pregnancy, breastfeeding and for 9 days after weaning (n = 7). Group 3: The mothers were kept on 10 mM PPi during pregnancy
(n = 9). Group 4: The mothers and the pups were kept on 1 mM PPi during pregnancy, breastfeeding, and for 9 days after weaning (n = 13). Group 5: The mothers
were kept on 1 mM PPi during pregnancy (n = 8).
B, C Typical Alizarin Red-stained sections of tissue blocks with the vibrissae of animals of different groups. Scale bar: 1 mm
D Calcification of renal arteries. The Enpp1+/ mothers were kept on tap water (n = 7) or on 0.3 mM PPi (n = 6) during pregnancy. Offspring was kept on tap water
for 55 days.
E Calcium content of the hind limb arteries. The heterozygous mothers were kept on tap water (n = 7) or 0.3 mM PPi (n = 6) during pregnancy. Offspring was kept
on tap water for 55 days.
F, G Typical kidney sections of a 55-day-old animal of the control group and of a 55-day-old animal from the group of 0.3 mM treatment only during pregnancy.
Sections were stained by the Yasue procedure. Scale bar: 200 lm.
H, I Typical Alizarin Red-stained hind limb arteries of a 55-day-old animal of the control group and those of a 55-day-old animal from the group of 0.3 mM treatment
only during pregnancy. Scale bar: 1 mm.
Data information: Data were analyzed by two-tailed Mann–Whitney nonparametric test. Results are expressed as mean  SEM.
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22-week-old animals. Calcification of the vibrissae of Enpp1/
mice was determined in 30-day-old animals. Calcification of the
hind limb and kidney arteries of Enpp1/ mice was quantified
in 55-day-old animals.
All animals were housed in approved animal facilities at the
Research Centre for Natural Sciences, Hungarian Academy of Sciences.
Mice were kept under routine laboratory conditions with 12-hour
light–dark cycle with ad libitum access to water and chow. Cryo-injury
was performed as described previously (Brampton et al, 2014).
Oral uptake of tetrasodium pyrophosphate in humans
Nine or ten healthy volunteers (age 24–69, fasting) ingested a
tetrasodium pyrophosphate solution containing 40 mg/kg or
67 mg/kg or 98 mg/kg (43, 72, 110 mM, pH 8.0, respectively).
The ingested amounts of tetrasodium pyrophosphate correspond
to 13–33% of the maximal tolerable daily intake published by the
World Health Organization, WHO (http://www.inchem.org/docu
ments/jecfa/jeceval/jec_2259.htm). The duration of ingestion was
less than one minute. Blood samples were collected before inges-
tion (0 min) and 30, 60, 120, 240, 360, and 480 min after from
the vena cubiti.
Pyrophosphate and plasma PPi assay
Sodium pyrophosphate tetrabasic decahydrate (BioXtra quality) was
purchased from Sigma and used in animal experiments. For human
absorption studies, tetrasodium pyrophosphate anhydrous, Code 118
was purchased from ICL Food Specialist (St. Louis, Missouri, USA).
Determination of PPi concentration in plasma was performed as
described (Jansen et al, 2014). Aliquots from the drinking water
during the animal studies were checked for the PPi concentration
and found to be stable for at least 4 days. PPi-containing drinking
water was changed every second day.
Ca-measurement
Hearts of Abcc6/ mice and the tissue blocks harboring the vibris-
sae of Enpp1/ mice were digested in 0.15 N HCl for 48 h, and the
calcium content was determined by complexometry using the Stan-
bio Calcium LiquiColor kit (Boerme, TX, USA) following the manu-
facturer’s instructions.
Calcification of the vibrissae of Abcc6/ mice was quantified by
histochemistry as described (Klement et al, 2005). Tissue blocks
with the hair capsules (vibrissae) were removed, paraffin-
embedded, sectioned, and stained with Alizarin Red to visualize
calcium deposits. The extent of calcification was quantified by
morphometry utilizing image analysis software FIJI (Schindelin
et al, 2012). The extent of calcification around the vibrissae was
quantified by two investigators in a blinded fashion.
Determination of calcification of arteries in the hind limb of
Enpp1/ mice was performed by Alizarin Red staining as described
in Kauffenstein et al (2014). Individual images of the arteries were
combined using Hugin-Panorama photo stitcher (Free Software
Foundation, Inc., Boston, MA USA). The resulting images were then
processed using ImageMagick (https://www.imagemagick.org).
Kidney tissue sections, 4 lm, were stained by the Yasue proce-
dure as described (Letavernier et al, 2016). Sections were
perpendicular to interlobar arteries and 500 lm away from renal
hilum. A morphometric analysis was performed (7–13 fields) by
using FIJI software (Schindelin et al, 2012). Results are expressed as
the ratio of calcified area indexed to the whole kidney tissue area.
Statistical analysis
Data were analyzed by two-tailed Mann–Whitney nonparametric test.
Values are expressed as mean  standard error of the mean (SEM). A
P < 0.05 was considered statistically significant, and the actual
P-values are indicated in the corresponding figures. Animal numbers
used for individual datasets varied and are shown in the figures.
Expanded View for this article is available online.
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The paper explained
Problem
Pyrophosphate (PPi), a natural metabolite, is known to inhibit the
pathological calcification of soft tissues including smooth muscle cells
of the arteries and several calcification disorders, caused by insuffi-
cient levels of PPi. However, it was always assumed that PPi is thera-
peutically inefficacious when orally taken because its bioavailability is
negligible.
Results
Orally given PPi appears in the circulation and substantially increases
plasma PPi concentrations to levels that are expected to inhibit the
soft tissue mineralization seen in several hereditary ectopic calcifi-
cation disorders. We further show that calcification is strongly attenu-
ated in mouse models of two inherited calcification disorders,
pseudoxanthoma elasticum and generalized arterial calcification of
infancy, when PPi was provided in the drinking water.
Impact
Our results suggest that oral PPi has potential as an effective, simple,
and low-cost treatment for patients with conditions involving connec-
tive tissue and vascular calcification. The risk of oral administration
PPi to patients is probably negligible as it is generally recognized to
be safe by FDA.
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